The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | India’s first sequential hematopoietic stem cell and kidney transplant for multiple myeloma
Lalit Kumar, MD, MBBS, All India Institute of Medical Sciences, New Delhi, India, discusses a case study of a 35-year-old woman with multiple myeloma (MM). She was initially treated with bortezomib, dexamethasone, and cyclophosphamide, followed by an autologous stem cell transplant (autoSCT), which improved her myeloma but not her renal function. Subsequently, she underwent a successful kidney transplant and is now doing well. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
